why is sucrose test a screening test for PNH

Reading File

Finding Sources

Reading File

Here is a comprehensive explanation:

Sucrose Test as a Screening Test for PNH

The Principle

The sucrose (sugar water) hemolysis test works on the following principle:

When red blood cells (RBCs) are suspended in an isotonic sucrose solution (low ionic strength), complement is activated via the alternative pathway at a lower threshold than normal. In PNH, RBCs lack GPI-anchored complement regulatory proteins — specifically CD55 (DAF) and CD59 (MIRL) — which normally protect the cell membrane from complement-mediated lysis.

CD55 (Decay Accelerating Factor) inactivates C3/C5 convertase complexes
CD59 (Membrane Inhibitor of Reactive Lysis) blocks assembly of the membrane attack complex (C5b-9)

Without these, even the mild complement activation triggered by low ionic strength is enough to lyse PNH red cells. Normal red cells are not lysed under these same conditions.

Why It Is a Screening Test (Not Confirmatory)

Feature	Sucrose Test	Ham's Test (Acidified Serum)
Sensitivity	High (sensitive)	High (sensitive)
Specificity	Lower (false positives)	Higher
Role	Screening	Confirmatory
Mechanism	Low ionic strength activates complement mildly	Acidified serum activates complement via alternative pathway
False positives	Megaloblastic anemia, autoimmune hemolytic anemia	Fewer

The sucrose test is sensitive but not specific — it can be positive in conditions other than PNH (e.g., megaloblastic anemia). This is precisely why it serves as a screening tool: a positive result prompts further confirmatory testing with the Ham test or flow cytometry.

Notably, Harrison's states: "The sucrose hemolysis test is unreliable; in contrast, the acidified serum (Ham) test is highly reliable." — Harrison's Principles of Internal Medicine 22E

An Important Distinguishing Point

The sucrose test is negative in HEMPAS (CDA type II), even though the Ham test (acidified serum) is positive in both PNH and HEMPAS. This makes the sucrose test useful for differentiating the two:

PNH → sucrose test positive
HEMPAS → sucrose test negative — Quick Compendium of Clinical Pathology, 5th ed.

Current Status

Both the sucrose test and Ham test have been largely replaced by flow cytometry, which is now the gold standard. Flow cytometry directly detects the absence of GPI-anchored proteins (CD55, CD59, CD14, CD24) on RBCs, granulocytes, and monocytes — and using FLAER (fluorescein-labeled aerolysin), which binds selectively to the GPI anchor itself, offers even higher sensitivity for detecting minor PNH clones. — Henry's Clinical Diagnosis and Management by Laboratory Methods

Summary: The sucrose test is a screening test for PNH because it is sensitive (picks up most PNH cases) but not specific (can be falsely positive in other conditions). It uses low ionic strength to gently activate complement, exposing the complement-defenseless GPI-deficient PNH red cells to lysis. A positive result must always be confirmed by the Ham test or flow cytometry.

how sucrose activates compliment ?

Finding Sources

The textbooks don't go into the detailed mechanism of how sucrose activates complement — this is a fairly specialized biochemical point not elaborated in the available references. I'll explain it from established knowledge.

How Sucrose "Activates" Complement in the Sucrose Test

The short answer: sucrose doesn't directly activate complement. Instead, it creates a low ionic strength environment that lowers the threshold for the alternative complement pathway to deposit C3b on cell surfaces — and in PNH cells, there is no CD55/CD59 to stop what happens next.

Here's the mechanism step by step:

1. Low Ionic Strength from Sucrose Solution

The test uses an isotonic but low ionic strength sucrose solution (sucrose is electrically neutral — it has no ions). Normal isotonic saline contains Na⁺ and Cl⁻ ions; sucrose solution does not. So the osmolality is maintained (cells don't lyse from osmotic shock), but the ionic strength is very low.

2. Effect of Low Ionic Strength on Complement

In a low ionic strength environment:

The electrostatic repulsion between complement proteins and the cell surface is reduced
This allows complement proteins to bind more readily to cell membranes
Specifically, it promotes C3 binding and deposition onto the RBC surface via the alternative pathway's "tick-over" mechanism — the slow, spontaneous hydrolysis of C3 into C3(H₂O) that happens continuously in plasma

Low ionic strength essentially amplifies the background alternative pathway activity that exists at all times, tipping C3b deposition toward the cell surface.

3. Why Normal Cells Are Unaffected

Normal RBCs have CD55 and CD59:

CD55 degrades C3 convertase (C3bBb) — stopping the amplification loop
CD59 blocks the membrane attack complex (MAC, C5b-9) from inserting into the membrane

Even with slightly enhanced C3 deposition in sucrose solution, normal cells survive because these regulators shut it down.

4. Why PNH Cells Lyse

PNH cells lack GPI-anchored CD55 and CD59 entirely. So:

The modest C3b deposition triggered by low ionic strength goes unchecked
The alternative pathway amplification loop runs freely
MAC (C5b-9) assembles on the RBC membrane
The cell lyses → hemolysis

Analogy

Think of the alternative pathway as a pilot light always burning at low level. Normally, CD55 and CD59 act as a fire extinguisher — any spark is immediately suppressed. Sucrose solution turns up the gas slightly (more C3b lands on the surface). For normal cells, the extinguisher handles it. For PNH cells, there is no extinguisher, so even the slightly bigger spark causes a fire.

Key Point for Exams

The sucrose test does not require exogenous complement or acidification — it simply exploits the fact that low ionic strength lowers the activation threshold of the naturally present complement in autologous serum. This is a gentler stimulus than the Ham test (which uses acid to directly activate complement), which is why the sucrose test is more sensitive but less specific — it can occasionally cause false-positive lysis in other conditions with complement-sensitive RBCs (e.g., megaloblastic anemia).

g6pd pathophyzuology

Finding Sources

Reading File

Loading Image

G6PD Deficiency — Pathophysiology

The Normal Role of G6PD

In the pentose phosphate pathway (PPP), G6PD catalyzes the first and rate-limiting step:

Glucose-6-phosphate + NADP⁺ → 6-phosphogluconolactone + NADPH + H⁺

The NADPH produced is used by glutathione reductase to regenerate reduced glutathione (G-SH) from oxidized glutathione (G-S-S-G). G-SH is then used by glutathione peroxidase to neutralize hydrogen peroxide (H₂O₂) and other reactive oxygen species (ROS):

H₂O₂ + 2 G-SH → 2 H₂O + G-S-S-G

Pathways of glucose 6-phosphate metabolism in the erythrocyte

Glucose 6-phosphate metabolism in the erythrocyte — Biochemistry, Lippincott Illustrated Reviews, 8th ed.

Why RBCs Are Uniquely Vulnerable

Two critical reasons:

The PPP is the ONLY source of NADPH in RBCs. Other cells have alternative NADPH-generating pathways (e.g., malic enzyme). RBCs do not.
RBCs have no nucleus or ribosomes — they cannot synthesize new G6PD enzyme. As the existing enzyme degrades (especially unstable mutant variants), protection against oxidative stress is irreversibly lost.

— Biochemistry, Lippincott Illustrated Reviews, 8th ed.

What Happens in G6PD Deficiency

When an oxidant stress hits (drug, infection, fava beans):

Step	Event
1	Oxidant stress → H₂O₂ and free radicals generated inside RBC
2	G6PD is deficient → NADPH cannot be regenerated
3	Without NADPH → G-SH pool is depleted
4	H₂O₂ accumulates → oxidizes hemoglobin sulfhydryl groups
5	Oxidized Hb denatures → forms Heinz bodies (insoluble precipitates attached to RBC membrane)
6	Membrane proteins are also oxidized → membrane rigidity increases
7	Rigid, Heinz body-laden RBCs are trapped and destroyed by macrophages in the spleen → extravascular hemolysis
8	Severe cases → intravascular hemolysis as well

Precipitating Factors

Oxidant drugs — sulfonamides, dapsone, primaquine, nitrofurantoin, rasburicase
Fava beans (favism) — contain vicine and convicine, which are oxidant compounds; particularly associated with the Mediterranean G6PD variant
Infections — macrophages generate free radicals during the inflammatory response; these diffuse into RBCs causing oxidative damage

G6PD Variants and Severity

Class	Residual Enzyme Activity	Clinical Features
I	<10%	Chronic non-spherocytic hemolytic anemia (CNSHA)
II*	<10%	Severe acute hemolytic anemia (e.g., Mediterranean variant)
III*	10–60%	Moderate (e.g., G6PD A−, common in Africa)
IV	>60%	Asymptomatic

Classes II and III are the most clinically common.

The G6PD A− variant (common in African populations) affects mainly older RBCs (which have lower enzyme activity normally due to enzyme decay), so young RBCs survive — hemolysis is self-limiting. The Mediterranean variant has more severely reduced activity affecting all RBCs, causing more prolonged hemolysis.

Inheritance

X-linked recessive → predominantly affects males. Females can be mildly affected if heterozygous (mosaic expression due to X-inactivation) or homozygous.

Evolutionary Note

G6PD deficiency persists at high frequency in malaria-endemic regions because Plasmodium falciparum infection induces oxidant stress inside parasitized RBCs — in G6PD-deficient cells, the parasite's own oxidative load destroys the host cell before the parasite can complete its life cycle, conferring partial protection against malaria. — Biochemistry, Lippincott Illustrated Reviews, 8th ed.

The enzyme deficiency test is usually not done during an active state, but it is done after resolution of an active phase, or it may be performed weeks after the hemolytic episode results. That's because during an active state, all the G6PD deficiency enzymes are hemestep and it doesn't show properly or what is the reason, I forgot.

Finding Sources

Reading File

You remembered the concept correctly. Here is the precise explanation:

Why G6PD Testing Is Unreliable During an Acute Hemolytic Episode

The Core Reason: Selective Destruction of the Most Deficient Cells

G6PD enzyme activity normally declines as RBCs age. In G6PD deficiency, this decline is accelerated — older RBCs have the lowest (or zero) G6PD activity and are the most vulnerable to oxidant stress.

During an acute hemolytic episode:

The oldest, most G6PD-deficient RBCs are selectively destroyed first (they have the least enzyme activity and cannot withstand the oxidant load)
The bone marrow responds by releasing a surge of reticulocytes and young RBCs into the circulation
Young RBCs naturally have higher G6PD activity — even in G6PD-deficient individuals, young cells haven't yet run down their enzyme supply

The Result: A False-Normal Test

When you measure G6PD activity at this point, the sample is enriched with young cells with relatively higher enzyme levels. The assay reads as falsely normal (or borderline), masking the true deficiency.

"During an acute hemolytic episode, the assay would measure the enzyme activity present in reticulocytes where there are usually normal levels, resulting in a falsely normal assay." — Creasy & Resnik's Maternal-Fetal Medicine

"The oldest, most G6PD-deficient red cells have been selectively destroyed, and young red cells, having higher G6PD activity, are being released into the circulation. Under these conditions, only a quantitative test can give a definitive result." — Harrison's Principles of Internal Medicine, 22nd ed.

When to Test

Wait 2–3 months after the hemolytic episode, when the RBC population has normalized and older cells (with low G6PD) are again present in adequate numbers
If you must test urgently, use a quantitative assay (not a screening/spot test), which is more sensitive and may still detect deficiency even in a reticulocyte-rich sample
DNA-based testing is not affected by the RBC age distribution and can diagnose at any time

Summary in One Sentence

During hemolysis, the deficient old cells are gone and young cells (with relatively normal G6PD) flood the blood — so the enzyme looks normal when it isn't. Testing must wait until the RBC population returns to its steady state.

to write in mz note one line above concept '

Here it is as a one-liner for your notes:

G6PD enzyme assay is done after resolution of acute hemolysis (not during) because selective destruction of oldest/most-deficient RBCs + reticulocytosis causes falsely normal enzyme levels.

Why parvovirus B19 infects progenitor erythroid cells or red cells and causes a temporary halt of erythropoiesis, usually leading to significant anemia in a setting of a pre-existing marrow stress, maybe like sickle cell anemia or something like that? Can you explain it a bit, why it's unaffected only progenitor red cells and why not progenitor white blood cells or platelet cells?

Finding Sources

Reading File

Excellent sources. Here is the full explanation:

Why Parvovirus B19 Selectively Targets Erythroid Progenitors

The Receptor is the Key: P Antigen (Globoside)

Parvovirus B19 can only infect cells that display its specific receptor on their surface — globoside (blood group P antigen). This is the entire reason for its selective tropism.

The virus's VP2 capsid protein binds to globoside → enters the cell → delivers its single-stranded DNA to the nucleus → hijacks host DNA and RNA polymerases to replicate → assembles new virions in the nucleus → lyses the cell upon release.

Cells that express globoside/P antigen include:

Erythroid progenitors and erythroblasts — highest expression → primary target
Megakaryocytes — express globoside too (more on this below)
Endothelial cells
Fetal myocardial cells

Cells that do not meaningfully express P antigen:

Myeloid progenitors (neutrophil/monocyte lineage)
Lymphoid progenitors

This is why the virus almost exclusively wipes out the erythroid lineage — it physically cannot enter cells lacking P antigen. Individuals who are naturally P antigen-negative (rare blood group phenotypes p or P1k) are actually resistant to B19 infection entirely.

— Sherris & Ryan's Medical Microbiology, 8th ed.; Creasy & Resnik's Maternal-Fetal Medicine

Why Does It Halt Erythropoiesis?

The virus specifically targets mitotically active immature erythroid progenitors in the bone marrow (CFU-E, pro-erythroblasts). Once infected:

The cell ceases to proliferate and is lysed
Erythroid output from the marrow drops to near zero
Reticulocytes disappear from the peripheral blood within days
This is called pure red cell aplasia (PRCA) — only the red cell lineage is affected

In a healthy person, RBCs live ~120 days. A 7–10 day shutdown of erythropoiesis causes only a trivial ~1% drop in hemoglobin — barely noticeable. The bone marrow recovers once the immune system clears the virus.

Why It Becomes Catastrophic in Underlying Hemolytic Conditions

In diseases like sickle cell anemia, hereditary spherocytosis, thalassemia, or G6PD deficiency:

RBCs are being destroyed much faster than normal (lifespan reduced from 120 days to sometimes 10–20 days)
The bone marrow is already running at maximum compensatory overdrive — producing red cells 6–8× the normal rate just to maintain baseline hemoglobin
There is no reserve capacity

When B19 now shuts down erythroid production for even 7–10 days:

The hemoglobin crashes rapidly and severely → Transient Aplastic Crisis (TAC)

This can be life-threatening, requiring emergency transfusion. The anemia develops faster than the immune system can clear the virus.

— Harrison's Principles of Internal Medicine, 22nd ed.; Sherris & Ryan's Medical Microbiology

What About Platelets and White Cells?

Lineage	P Antigen Expression	Effect of B19
Erythroid progenitors	High	Directly lysed → aplasia
Megakaryocytes (platelet precursors)	Present	Can be infected, but less efficiently
Myeloid progenitors (WBC)	Absent/minimal	Not infected
Lymphoid progenitors	Absent	Not infected

Megakaryocytes do express some globoside, which is why mild thrombocytopenia is occasionally seen in B19 infection. However, this is not the dominant effect because the expression level is lower and megakaryocytes are less critical in the same way. The WBC lineage (granulocyte/monocyte/lymphocyte progenitors) is essentially spared because they simply don't have the receptor.

The rare cases of autoimmune neutropenia and thrombocytopenia seen with B19 are immune-mediated (molecular mimicry, cross-reactive antibodies) — not from direct viral cytotoxicity.

One-Line Summary for Notes

B19 targets only erythroid progenitors because they uniquely express its receptor (P antigen/globoside) in high density; in normal persons the 7–10 day RBC production halt is trivial, but in compensated hemolytic anemia (where the marrow runs at maximum rate), even brief shutdown causes precipitous hemoglobin drop → transient aplastic crisis.

MONOSPOT OR heterophile agglutation test explainn why heterophile ? Inf mononucleosis

Finding Sources

Reading File

Here is the full explanation:

Monospot / Heterophile Agglutination Test in Infectious Mononucleosis

What Does "Heterophile" Mean?

The word heterophile (Greek: hetero = different, phile = loving) refers to antibodies that cross-react with antigens from a completely different, unrelated species.

In other words: the antibodies produced during EBV infection in a human patient happen to recognize and bind to antigens on sheep, horse, and ox red blood cells — which are phylogenetically unrelated. There is no logical evolutionary reason for this — it is a quirk of molecular mimicry where certain carbohydrate/surface antigens on animal RBCs structurally resemble something triggered during EBV infection.

Why Does EBV Cause Heterophile Antibodies?

EBV infects B lymphocytes (via CD21 receptor). This causes polyclonal B cell activation — meaning B cells are mass-stimulated to produce a wide variety of antibodies in a non-specific, chaotic fashion, not just antibodies targeted at EBV itself.

Among the flood of antibodies produced during this polyclonal B cell activation, some happen to be IgM antibodies that cross-react with a carbohydrate antigen shared between:

Human EBV-infected cells
Red blood cells of sheep, horses, and cattle

These are the heterophile antibodies (also called Paul-Bunnell antibodies).

Key point: heterophile antibodies are not directed against EBV — they are a byproduct of nonspecific B cell activation. They do not correlate with disease severity and are not protective. — Sherris & Ryan's Medical Microbiology, 8th ed.

How the Monospot Test Works

The Monospot is a rapid slide agglutination test:

A drop of patient serum is placed on a card/slide
It is first mixed with guinea pig kidney cells — these absorb away cross-reacting antibodies from serum sickness and other conditions (specificity step)
Then horse RBCs (or sheep RBCs in older versions) are added
If heterophile antibodies are present → they agglutinate the horse RBCs → positive result

The guinea pig kidney absorption step is the trick that makes it specific: serum sickness also produces heterophile-like antibodies, but those ARE absorbed by guinea pig kidney cells. EBV heterophile antibodies are not absorbed by guinea pig kidney → they remain and cause agglutination → positive monospot.

Why Called "Heterophile Agglutination"?

Term	Meaning
Heterophile	Antibodies that react with antigen from a different species
Agglutination	Clumping/aggregation of RBCs by the antibody

So the test = agglutination of animal (horse) RBCs by human antibodies that were cross-reactively produced during EBV infection = heterophile agglutination.

Performance of the Test

Feature	Value
Sensitivity	~75–85% (adults); only ~40% in children; <20% in children <4 yrs
Specificity	~90%
Antibody type	IgM
Appears	Week 1–2 of illness
Peaks	Week 2–3
Persists	Up to 3–6 months

False positives: HIV, SLE, rubella, lymphoma, viral hepatitis False negatives: early disease, young children (children mount a weaker heterophile response)

When monospot is negative but mononucleosis is strongly suspected → send EBV-specific serology (VCA-IgM, VCA-IgG, EA, EBNA).

— Quick Compendium of Clinical Pathology, 5th ed.; Harrison's, 22nd ed.

One-Line Summary for Notes

Heterophile = IgM antibodies produced by nonspecific polyclonal B cell activation during EBV infection that cross-react with antigens on unrelated species (horse/sheep RBCs); the Monospot detects these by agglutination after absorbing out non-specific antibodies with guinea pig kidney.

Cd34= means hematopoietic stem cells, Cd55 meand DAF CD19 and IL5 , CD21 iam so confudssed can you create a notes with all this imp markers amd what i shou;ld know to siolve usmle question immunolgy

Finding Sources

Reading File

Finding Sources

Reading File

I now have enough from the textbooks to build a comprehensive, USMLE-focused CD marker reference. Let me compile this.

USMLE CD Marker Master Notes

HOW TO THINK ABOUT CD MARKERS

CD markers = proteins on cell surfaces. They tell you what the cell IS and what it DOES. On USMLE, questions give you a CD pattern → you identify the cell or disease.

T CELL MARKERS

Marker	Cell	What to Know
CD3	All T cells	Forms complex with TCR. Pan-T cell marker — if it's a T cell, it has CD3. Loss of CD3 = no T cell signaling
CD4	Helper T cells	Binds MHC II. Also the receptor HIV gp120 binds (with CCR5/CXCR4 as co-receptor). CD4 count monitors HIV progression
CD8	Cytotoxic T cells	Binds MHC I. Kills virus-infected and tumor cells
CD28	All T cells (CD4 > CD8)	Costimulatory receptor on T cells. Binds B7 (CD80/86) on APCs → Signal 2 for T cell activation. Without it → T cell anergy
CD40L (CD154)	Activated CD4⁺ T cells	Binds CD40 on B cells → triggers B cell class switching. Hyper-IgM syndrome = CD40L deficiency → can't switch from IgM to IgG/IgA/IgE
CD25	Activated T cells & Tregs	IL-2 receptor α-chain. Tregs = CD4⁺CD25⁺FoxP3⁺
CD45RA	Naïve T cells	"RA = Raw/new"
CD45RO	Memory T cells	"RO = Old/memory"
CD1	Developing T cells, Langerhans cells	Presents lipid antigens (like mycobacterial antigens) — MHC I-like
CD2	T cells, NK cells	Adhesion molecule; marker of T cell activation
CD7	T cells, stem cells	Marker for T-cell ALL and stem cell leukemia

B CELL MARKERS

Marker	Cell	What to Know
CD19	All B cells (not plasma cells)	Pan-B cell marker. Part of B cell co-receptor complex (with CD21 + CD81). Target of rituximab in lymphoma treatment
CD20	Pre-B → mature B cells (not plasma cells)	Rituximab target. Lost when B cell becomes plasma cell (that's why rituximab doesn't kill plasma cells)
CD21	Mature B cells, follicular dendritic cells	CR2 = Complement receptor 2 — binds C3d. Also the EBV receptor (EBV binds CD21 to enter B cells → infectious mononucleosis)
CD40	B cells, macrophages, dendritic cells	Receives signal from CD40L on T helper cells → class switching
CD10	Pre-B cells, germinal center B cells	Marker for ALL (B cell) and follicular lymphoma
CD5	T cells + some B cells (B-1 cells)	B cells expressing CD5 → seen in CLL and mantle cell lymphoma
CD23	B cells, macrophages, eosinophils	Low-affinity IgE receptor (FcεRII). Elevated in CLL (CLL = CD5⁺ CD23⁺)
CD38	Early B and T cells, plasma cells	Marker for plasma cells and multiple myeloma. Target of daratumumab
CD138 (Syndecan-1)	Plasma cells	Definitive plasma cell marker. Positive in multiple myeloma

NK CELL MARKERS

Marker	Cell	What to Know
CD16	NK cells, macrophages	FcγRIII — binds IgG Fc → mediates ADCC (antibody-dependent cellular cytotoxicity)
CD56	NK cells	Pan-NK marker. Also seen in NK/T cell lymphoma
CD57	NK cells, some T cells	Mature NK cells

MYELOID / MONOCYTE MARKERS

Marker	Cell	What to Know
CD14	Monocytes, macrophages	LPS (endotoxin) co-receptor. GPI-anchored — absent in PNH
CD15	Granulocytes	Marker for Reed-Sternberg cells in Hodgkin lymphoma (CD15⁺ CD30⁺)
CD30	Activated T/B cells	Reed-Sternberg cells in Hodgkin lymphoma (CD15⁺ CD30⁺). Target of brentuximab vedotin
CD64	Monocytes, macrophages	High-affinity FcγRI
CD11b / CD18	Neutrophils, macrophages	Integrin — mediates adhesion. Deficiency → LAD (Leukocyte Adhesion Deficiency)

STEM CELL / PROGENITOR MARKERS

Marker	Cell	What to Know
CD34	Hematopoietic stem cells	The HSC marker. Used to identify and isolate stem cells for transplant. Stains HSC-derived tumors (e.g., some AML, GIST also CD34⁺)
TdT (Terminal deoxynucleotidyl transferase)	Pre-T, Pre-B cells	Enzyme in immature lymphocytes. Positive in ALL, negative in mature lymphomas

COMPLEMENT REGULATORY PROTEINS (GPI-anchored — critical for PNH)

Marker	Cell	What to Know
CD55 (DAF — Decay Accelerating Factor)	All blood cells	Degrades C3/C5 convertase → stops complement amplification. Absent in PNH → complement-mediated hemolysis
CD59 (MIRL — Membrane Inhibitor of Reactive Lysis)	All blood cells	Blocks MAC (C5b-9) assembly. Absent in PNH — most important protein protecting RBCs. GPI-anchored
CD35 (CR1)	RBCs, B cells, monocytes	Complement receptor 1 — binds C3b/C4b → phagocytosis

PNH high-yield: PNH = loss of all GPI-anchored proteins (due to PIG-A mutation) → CD55 and CD59 absent → uncontrolled MAC → intravascular hemolysis. Flow cytometry showing absent CD55/CD59 = gold standard diagnosis.

ADHESION / TRAFFICKING MARKERS

Marker	Cell	What to Know
CD11a/CD18 (LFA-1)	Leukocytes	Binds ICAM-1. Required for leukocyte extravasation. Absent in LAD type I
CD31 (PECAM-1)	Endothelial cells, platelets	Mediates leukocyte migration through vessel walls
CD62L (L-selectin)	Naïve lymphocytes	Homing receptor for lymph nodes — naïve T cells use this to enter lymph nodes

CYTOKINE RECEPTORS (USMLE-RELEVANT)

Marker	Cytokine	Key Disease
CD25	IL-2 receptor α	Tregs = CD4⁺ CD25⁺ FoxP3⁺
CD122	IL-2/IL-15 receptor β	NK and memory T cell survival
CD127	IL-7 receptor	Critical for T cell development in thymus
CD132	Common γ chain (γc)	Shared by IL-2, IL-4, IL-7, IL-9, IL-15, IL-21 receptors. X-linked SCID = γc deficiency → no T, B (dysfunctional), NK cells

IL-5 receptor: on eosinophils and basophils. IL-5 = the eosinophil growth/activation cytokine. IL-5 blockade (mepolizumab) treats severe eosinophilic asthma.

DISEASE-MARKER QUICK LOOKUP

Disease / Scenario	Key Markers
T-ALL	TdT⁺, CD7⁺, CD3⁺, CD4⁺CD8⁺ (double positive)
B-ALL	TdT⁺, CD19⁺, CD10⁺ (CALLA), CD20⁺
CLL	CD5⁺, CD19⁺, CD20(dim)⁺, CD23⁺, TdT⁻
Mantle Cell Lymphoma	CD5⁺, CD19⁺, CD20⁺, CD23⁻, Cyclin D1⁺
Follicular Lymphoma	CD10⁺, CD19⁺, CD20⁺, BCL-2⁺
Multiple Myeloma	CD138⁺, CD38⁺, CD19⁻, CD20⁻
Hodgkin Lymphoma (RS cells)	CD15⁺, CD30⁺, CD45⁻
PNH	CD55⁻, CD59⁻ on RBCs/WBCs
LAD	CD11b/CD18⁻ (integrin absent)
X-linked SCID	CD132 (γc) deficiency
Hyper-IgM syndrome	CD40L (CD154) deficiency on T cells
HIV target cell	CD4⁺ T cell (gp120 binds CD4 + CCR5/CXCR4)
EBV entry into B cells	CD21 (EBV receptor)
Rituximab target	CD20 (B cells in lymphoma/RA)

ONE-LINE MNEMONICS

CD3 = TCR's partner (always together, always T cell)
CD4 = "4 letters in HELP" → helper; also HIV's door
CD8 = "8 = kill" → cytotoxic killer
CD19/20 = B cell's ID card (lost when becoming plasma cell)
CD21 = EBV + C3d receptor (2 jobs, 1 marker)
CD34 = Stem cell marker (think: "34 = stem")
CD55/59 = PNH's missing bodyguards
CD40L = T cell's signal to B cell ("switch now!") → absent = Hyper-IgM

we have generally have a high leukocyte concentration, which will lead to generalized erythema against acute compared to chronic erythrocytosis, we have a filamented there, with the bulb is enlarged rather than white bulb in contrast to all other chronic leukemias. And, yeah, can you break that down Hy sticky notes usmle

Finding Sources

I have everything needed. Here are your USMLE sticky notes:

🗒️ STICKY NOTES: Acute vs Chronic Leukemia — USMLE Smear Findings

CONCEPT 1 — Why Acute Leukemia Has HIGH WBC + Leukostasis

In acute leukemia, the marrow pumps out massive numbers of immature blasts that cannot mature → WBC count skyrockets.

When WBC >100,000/μL → LEUKOSTASIS:

Blasts are large, rigid, sticky → clog microcirculation
Symptoms: hypoxia, dyspnea (pulmonary), confusion/seizures (CNS), visual changes
AML gets leukostasis at lower counts than ALL (myeloblasts are bigger/stickier than lymphoblasts)
CLL patients can tolerate WBC >500,000 without leukostasis — mature small lymphocytes are small and deformable

USMLE tip: Young patient, very high WBC, confusion + hypoxia = leukostasis → emergency leukapheresis

CONCEPT 2 — The Blast Cell: What That "Large Nucleus With Prominent Nucleolus" Means

This is what you saw — "enlarged nucleus" = BLAST morphology

Feature	Blast (Acute)	Mature cell (Chronic)
Nucleus size	Large — fills most of the cell	Smaller, condensed
Nuclear chromatin	Fine/open (euchromatin — active transcription)	Coarse/clumped (heterochromatin)
Nucleolus	Prominent, visible (1–3 nucleoli)	Absent or inconspicuous
N:C ratio	High — nucleus dominates, scant cytoplasm	Low — more cytoplasm
Maturity	Immature — stuck, cannot differentiate	Mature — functionally useless but morphologically complete

The "bulb" you described = the prominent nucleolus inside the large open nucleus of the blast. This is the hallmark of active, rapidly dividing, undifferentiated cells. The nucleolus = ribosome factory = cell is in overdrive growth mode.

CONCEPT 3 — Auer Rods (AML ONLY — never in ALL)

Pink/red needle-like rods in cytoplasm of myeloblasts
Made of fused primary azurophilic granules (myeloperoxidase-positive)
Pathognomonic for AML — if you see them, it's AML, period
Most abundant in APL (AML M3, t(15;17)) — bundles of Auer rods = "faggot cells"
APL + Auer rods = DIC risk (granules release procoagulants)

USMLE: Blast with rod-shaped pink cytoplasmic inclusion = AML → check for DIC

CONCEPT 4 — Smudge Cells (CLL — Chronic)

CLL lymphocytes are fragile → smear preparation crushes them → smudge/basket cells
Seen in CLL (and sometimes Waldenström's)
The opposite of blasts — these cells are mature but mechanically fragile
CLL smear = small mature lymphocytes + smudge cells

USMLE: Elderly patient, WBC 80,000, small lymphocytes, smudge cells on smear = CLL

CONCEPT 5 — The Core Difference: Acute vs Chronic at a Glance

	Acute Leukemia	Chronic Leukemia
Cell type	Blasts (immature, >20% in marrow)	Mature but clonal cells
Smear	Large cells, open chromatin, nucleoli, high N:C	Small/mature cells, condensed chromatin
WBC	Very high, very sick	Can be extremely high but asymptomatic longer
Onset	Sudden, weeks	Insidious, months-years
Leukostasis risk	HIGH (especially AML)	Low (CLL tolerates 500K+)
Special finding	Auer rods (AML)	Smudge cells (CLL)
Treatment urgency	Emergency	Often "watch and wait"

ONE-LINE EACH FOR NOTES

Blast = large nucleus + prominent nucleolus + scant cytoplasm + fine chromatin = immature = ACUTE leukemia
Auer rod = pink needle in cytoplasm = AML only → rule out APL (DIC risk)
Smudge cell = crushed fragile lymphocyte on smear = CLL
Leukostasis = WBC >100K + blasts (AML worse than ALL) → plugs microvessels → CNS + lung emergency
Chronic leukemia cells = mature-looking, condensed chromatin, no nucleolus, no Auer rods

Here I asked my presenter if you should give me a bit of chronic leukemia and rather chronic leukemia with hairy leukemia in general in PLL or in chronic leukemia, there will be an increased accumulation of the white blood cells, which is the lymphocytes in the white pulp of spleen and splenomegaly also present because all the cells get trapped with the lymphatic macrophages. And specifically, but here is the leukemia, there is no lymphadenopathy, and accumulation of hairy cells in the red pulp, why

Finding Sources

Reading File

Loading Image

Perfect. Now here is the full breakdown with sticky notes:

🗒️ STICKY NOTES: Hairy Cell Leukemia vs CLL — Spleen, Lymph Nodes & Why Red Pulp

FIRST — The Normal Spleen Architecture (to understand the difference)

Zone	What lives there normally
White pulp	Lymphocytes (T and B cells) — the immune zone
Red pulp	RBCs, macrophages, sinusoids — the filtration/blood zone
Marginal zone	Transition between the two

In CLL and most B cell lymphomas/leukemias, the neoplastic lymphocytes home to the white pulp — because that is where B cells normally reside and circulate. Lymphadenopathy also occurs because these cells traffic through lymph nodes normally.

WHY HAIRY CELLS GO TO THE RED PULP (not white pulp)

This is the key distinction and it comes down to cell surface receptors and trafficking signals.

Hairy cells express CD11c (integrin) and CXCR3 — adhesion/homing receptors that direct them toward sinusoids and vascular spaces rather than lymphoid follicles. Normal B cells home to white pulp follicles using CXCR5 and CCR7. Hairy cells do not follow that homing signal.

Additionally, hairy cells have those characteristic cytoplasmic projections ("hairs") — these are actually filamentous pseudopodia loaded with adhesion molecules (especially VLA integrins). These sticky projections physically anchor the cells into the splenic red pulp sinusoids and cords, where they become enmeshed.

The result:

Red pulp is massively infiltrated → white pulp is obliterated → spleen looks grossly beefy red (not the white-on-red pattern of CLL)

— Robbins & Cotran Pathologic Basis of Disease

WHY NO LYMPHADENOPATHY IN HAIRY CELL LEUKEMIA

This is the most clinically distinctive feature — and the reason is the same homing receptor logic:

Normal lymph node trafficking requires CCR7 (responds to CCL19/CCL21 chemokines secreted in lymph nodes)
Hairy cells do not express CCR7 → they cannot respond to the "come to the lymph node" signal
Without CCR7, they cannot enter lymph nodes via high endothelial venules (HEVs)
So lymph nodes are spared

In CLL, cells have CCR7 and CXCR5 → they DO traffic to lymph nodes → lymphadenopathy is prominent

USMLE high-yield: Massive splenomegaly + NO lymphadenopathy = think Hairy Cell Leukemia first

Hairy cell leukemia peripheral blood smear — A: phase contrast showing hair-like projections; B: stained smear showing round/folded nuclei, pale blue cytoplasm with irregular cytoplasmic borders

Hairy cell leukemia smear — Robbins, Cotran & Kumar

CLL vs HCL vs PLL COMPARISON TABLE

Feature	CLL	Hairy Cell Leukemia (HCL)	PLL (Prolymphocytic Leukemia)
Cell origin	Mature B cell	Mature B cell	Mature B cell (or T)
WBC count	Very HIGH (lymphocytosis)	LOW / pancytopenia	Very HIGH
Spleen	Enlarged (white pulp)	Massively enlarged (RED pulp)	Enlarged
Lymphadenopathy	Yes — prominent	No — absent/rare	Variable
Smear finding	Small round lymphocytes + smudge cells	Cells with hairy cytoplasmic projections, oval/reniform nucleus	Large cells with prominent single central nucleolus (>55% of cells)
Bone marrow	Infiltrated, aspiratable	Infiltrated + fibrosis → "dry tap"	Infiltrated
Monocytes	Normal	Monocytopenia (unique!)	Normal
Special stain	—	TRAP positive (tartrate-resistant acid phosphatase)	—
CD markers	CD5⁺, CD19⁺, CD20(dim)⁺, CD23⁺	CD19⁺, CD20⁺, CD11c⁺, CD25⁺, CD103⁺, CD5⁻, CD23⁻	CD19⁺, CD20(bright)⁺, FMC7⁺
Mutation	del(13q), del(11q), +12	BRAF V600E (>90%)	—
Treatment	Ibrutinib, venetoclax	Cladribine (purine analogue), BRAF inhibitor (vemurafenib)	—

WHY PANCYTOPENIA IN HCL (not just lymphocytosis like CLL)

Three hits at once:

Bone marrow infiltration → less space for normal hematopoiesis
Reticulin fibrosis (hairy cells secrete fibronectin) → marrow becomes fibrotic → dry tap → can't produce normal cells
Hypersplenism → enlarged spleen traps and destroys RBCs, platelets, neutrophils

Result: pancytopenia — low RBCs, low WBCs, low platelets — opposite of CLL's high lymphocyte count

Monocytopenia specifically = unique to HCL among all leukemias. The mechanism isn't fully understood but is very characteristic. It explains why HCL patients get atypical mycobacterial infections (monocytes/macrophages are needed to contain mycobacteria).

🗒️ ONE-LINE STICKY NOTES

HCL = Red pulp spleen (hairy cells home to sinusoids via CD11c/integrins, not white pulp follicles)
No lymphadenopathy in HCL = no CCR7 → can't enter lymph nodes
Dry tap = hairy cells + reticulin fibrosis → bone marrow can't be aspirated
TRAP stain positive = HCL (tartrate-resistant acid phosphatase)
BRAF V600E = HCL mutation (same as melanoma)
Monocytopenia = unique to HCL → atypical mycobacteria risk
CD103 positive = HCL marker (along with CD11c, CD25)
CLL spleen = white pulp; HCL spleen = red pulp — always on USMLE

This is a shared conversation. Sign in to Orris to start your own chat.